NCT02362035 - ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies | Biotech Hunter

Enrollment

161

Participants

Timeline

Start Date

February 20, 2015

Primary Completion Date

July 14, 2020

Study Completion Date

April 1, 2026

Conditions

Follicular Lymphoma (FL)CLLSmall Lymphocytic Lymphoma (SLL)Richter's SyndromeMantle Cell Lymphoma (MCL)Indolent Non Hodgkin LymphomaWaldenström MacroglobulinemiaMultiple MyelomaHodgkin LymphomaBurkitt LymphomaMarginal Zone LymphomasMediastinal Large B Cell LymphomaHairy Cell Leukemia

Interventions

DRUG

Acalabrutinib

Orally Administered (PO)

DRUG

Pembrolizumab

Intravenous Administered (IV)

Trial Locations (19)

2215

Research Site, Boston

20007

Research Site, Washington D.C.

22031

Research Site, Fairfax

24014

Research Site, Roanoke

29605

Research Site, Greenville

37203

Research Site, Nashville

43210

Research Site, Columbus

60714

Research Site, Niles

75246

Research Site, Dallas

75702

Research Site, Tyler

77030

Research Site, Houston

78217

Research Site, San Antonio

80218

Research Site, Denver

85704

Research Site, Tucson

90095

Research Site, Los Angeles

98684

Research Site, Vancouver

98902

Research Site, Yakima

55905-0001

Research Site, Rochester

68198-7680

Research Site, Omaha